EUVIMEDOpdag EUVIMED
MetaanalyseOpen access · CC BY-NC 4.0

Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial

Masashi Hasebe iD, Chen-Yang Su iD, Daisuke Yabe iD, Satoshi Yoshiji iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71035 ↗

At a glance

Metaanalyse in Diabetes, Obesity and Metabolism, 2026. Written by Masashi Hasebe and 3 co-authors. Institution: Canada Excellence Research Chair Program in Genomic Medicine, McGill University, Montréal, Québec, Canada. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Hypoglycemic Agents. Cited 1 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: CIHR, Canada Research Chairs Program, Japan Society for the Promotion of Science.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

To evaluate the cardiovascular efficacy and absolute benefit of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) by baseline estimated glomerular filtration rate (eGFR). Materials and Methods PubMed and EMBASE were searched to 29 April 2026 for randomized placebo‐controlled trials of GLP‐1RAs in adults with type 2 diabetes or overweight/obesity that reported eGFR‐stratified major adverse cardiovascular events (MACE). Hazard ratios (HRs) were extracted for eGFR < 60 and ≥ 60 mL/min/1.73 m 2 . Random‐effects meta‐analyses estimated pooled HRs within each eGFR stratum and the pooled ratio of HRs (RHR) comparing eGFR < 60 versus ≥ 60 mL/min/1.73 m 2 . Exploratory absolute risk reduction (ARR) and number needed to treat (NNT) were derived from placebo‐group MACE risk and the corresponding pooled HR.

Results

Nine publications from eight trials were included, comprising 70 822 participants; 70 534 had eGFR‐stratified MACE data. GLP‐1RAs similarly reduced MACE risk among participants with eGFR ≥ 60 and < 60 mL/min/1.73 m 2 , with pooled HRs of 0.83 (95% CI 0.77–0.90; p < 0.001; I 2 = 35.6%) and 0.83 (95% CI 0.74–0.93; p < 0.001; I 2 = 40.9%), respectively. The pooled RHR showed no evidence of effect modification (1.02, 95% CI 0.85–1.21; p = 0.84). ARR was larger with eGFR < 60 than ≥ 60 mL/min/1.73 m 2 (2.6% vs. 1.6%), corresponding to NNTs of 39 (95% CI 26–91) versus 62 (95% CI 46–101).

Conclusions

GLP‐1RAs reduced MACE risk similarly across eGFR strata, while lower eGFR was associated with a larger estimated absolute cardiovascular benefit. These findings support GLP‐1RA therapy in individuals with reduced kidney function.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Cardiovascular DiseasesHypoglycemic AgentsKidneyHumansRandomized Controlled Trials as TopicGlomerular Filtration RateObesity

Author keywords

GLP‐1 receptor agonistscardiovascular diseaseestimated glomerular filtration ratekidney functionmeta‐analysis

Substances

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Authors and institutions

  • Canada Excellence Research Chair Program in Genomic Medicine, McGill University, Montréal, Québec, Canada.
  • Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Diabetes and Endocrinology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka, Japan.
  • Department of Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.

ORCID profiles: Masashi Hasebe, Chen-Yang Su, Daisuke Yabe, Satoshi Yoshiji

Funding

  • CIHR
  • Canada Research Chairs Program
  • Japan Society for the Promotion of Science
  • McGill University
  • DNA to RNA Foundational Program
  • Canadian Institutes of Health Research

Cite

APA

Hasebe, M., Su, C. Y., Yabe, D., & Yoshiji, S. (2026). Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71035

Vancouver

Hasebe M, Su CY, Yabe D, Yoshiji S. Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71035

BibTeX
@article{Hasebe2026,
  author = {Hasebe, Masashi and Su, Chen-Yang and Yabe, Daisuke and Yoshiji, Satoshi},
  title = {Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71035}
}
Start for free →